NEMAURA MEDICAL INC (NMRD) Stock Overview
USA - NASDAQ:NMRD - US6404422080 - Common Stock
NMRD Key Statistics, Chart & Performance
The current stock price of NMRD is 0.1053 USD. In the past month the price decreased by -54.22%. In the past year, price decreased by -94.2%.
NMRD Latest News, Press Relases and Analysis
NMRD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.42 | 220.78B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.47 | 195.91B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.27 | 149.82B | ||
| SYK | STRYKER CORP | 29.71 | 145.96B | ||
| MDT | MEDTRONIC PLC | 16.94 | 120.15B | ||
| BDX | BECTON DICKINSON AND CO | 13.02 | 53.26B | ||
| IDXX | IDEXX LABORATORIES INC | 53.36 | 51.27B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.61 | 44.68B | ||
| RMD | RESMED INC | 27.17 | 37.87B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.77 | 35.68B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.26 | 27.76B | ||
| DXCM | DEXCOM INC | 41.37 | 27.58B |
Related stock screener links
About NMRD
Company Profile
Nemaura Medical, Inc. operates as a holding company. The company is headquartered in New York City, New York and currently employs 36 full-time employees. The company went IPO on 2014-11-04. The firm is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.
Company Info
NEMAURA MEDICAL INC
57 W 57th St
New York City NEW YORK 10019 US
CEO: Dewan Fazlul Hoque Chowdhury
Employees: 36
NEMAURA MEDICAL INC / NMRD FAQ
Can you describe the business of NEMAURA MEDICAL INC?
Nemaura Medical, Inc. operates as a holding company. The company is headquartered in New York City, New York and currently employs 36 full-time employees. The company went IPO on 2014-11-04. The firm is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.
What is the stock price of NEMAURA MEDICAL INC today?
The current stock price of NMRD is 0.1053 USD. The price decreased by -17.8% in the last trading session.
What is the dividend status of NEMAURA MEDICAL INC?
NMRD does not pay a dividend.
How is the ChartMill rating for NEMAURA MEDICAL INC?
NMRD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists NMRD stock?
NMRD stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of NEMAURA MEDICAL INC (NMRD)?
NEMAURA MEDICAL INC (NMRD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.39).
How many employees does NEMAURA MEDICAL INC have?
NEMAURA MEDICAL INC (NMRD) currently has 36 employees.
NMRD Technical Analysis
NMRD Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NMRD. NMRD has a bad profitability rating. Also its financial health evaluation is rather negative.
NMRD Financial Highlights
Over the last trailing twelve months NMRD reported a non-GAAP Earnings per Share(EPS) of -0.39. The EPS increased by 39.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -114.35% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NMRD Forecast & Estimates
7 analysts have analysed NMRD and the average price target is 8.67 USD. This implies a price increase of 8133.62% is expected in the next year compared to the current price of 0.1053.
For the next year, analysts expect an EPS growth of 42.95% and a revenue growth 43.63% for NMRD